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Introduction
Platelets play a fundamental pathophysiological role in patients with acute coronary syndrome. Following an atherosclerotic plaque rupture or erosion, platelet aggregation leads to thrombus formation and an acute ischemic event. (1) Ticagrelor is a direct acting and reversibly binding P2Y12 receptor inhibitor that is highly recommended in clinical guidelines for treatment of patients with acute coronary syndromes (ACS). (2) (3) (4) In patients with stable angina pectoris (SAP), administration of 180 mg loading dose (LD) of ticagrelor resulted in a more rapid and stronger inhibition of platelet reactivity (PR) compared to clopidogrel. Within 30 minutes, ticagrelor administration led to the same degree of inhibition of PR as that achieved 8 hours after a 600 mg LD of clopidogrel. (5) However, in patients with ST segment elevation myocardial infarction (STEMI), where fast and effective platelet inhibition is even more important, a delayed onset of action of platelet inhibitors, and a wider variability of drug response has been demonstrated. Beside the higher baseline PR in STEMI patients, a limited or delayed intestinal absorption of orally administered drugs is another major contributor to this observation. (6) (7) (8) Previous pharmacokinetic studies have demonstrated that chewable aspirin and crushed clopidogrel administration increased the rate of drug absorption compared to integral tablets, when administered orally. (9, 10) Recently, crushed ticagrelor tablets, administered orally or via a naso-gastric tube, has been shown to be feasible and resulted in increased plasma concentration of ticagrelor and its active metabolite at an earlier time point compared to integral tablets. (11, 12) As the plasma concentration of ticagrelor and its active metabolite is linearly associated with the degree of platelet inhibition, (2) administration of crushed or chewed ticagrelor may provide a more rapid onset of drug action. Nevertheless, limited pharmacodynamic data of novel methods of ticagrelor administration exist and data regarding chewed ticagrelor have not been reported.
Thus, the aim of our study was to provide pharmacodynamic data of two novel ways of ticagrelor administration, crushed and chewed tablets, in comparison with the standard, integral tablets administration.
Material and Methods

Study design and population
This was a single center, open-label, randomized, investigator initiated, pharmacodynamic study. Patients > 18 year of age, with stable angina pectoris, scheduled for outpatient coronary angiography, were randomly assigned, at least 90 minutes before the intervention, in a 3:1:1 fashion (according to a computer generated randomization list) to one of the following treatment modalities: A) Integral ticagrelor tablets, 180 mg LD B) Crushed ticagrelor tablets, 180 mg LD or C) Chewed ticagrelor tablets, 180 mg LD. The allocation sequence was concealed from the researcher enrolling and assessing participants in sequentially numbered, sealed envelopes. Exclusion criteria were: pregnancy or lactation, known allergy to the study medication, chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine, treatment with warfarin or new oral anticoagulants (NOAC) within 4 days before admission, active bleeding, bleeding diathesis or coagulopathy, history of gastrointestinal or genitourinary bleeding in the last 2 months, history of intracranial bleeding, major surgery in the last 4 weeks, known relevant hematological deviation (severe anemia, severe thrombocytopenia), known severe liver disease or severe renal failure, increased risk of bradycardia or inability to chew tablets.
Administration of the different ticagrelor formulations.
All three groups received two tablets of ticagrelor (180 mg) and 150 mL of water. In the first group (A), two integral ticagrelor tablets were administered as an oral dose, followed by 150 mL of water. In the second group (B), two ticagrelor tablets (180 mg) were placed in a pointof-care (POC) crushing device and crushed. The total content of the crushed tablets was transferred to a dosing cup, 50 mL of water was added and the suspension was mixed before drinking. Afterwards, 100 mL of water was administered. In the third group (C), the patient was instructed to chew two tablets of ticagrelor for at least 10-15 seconds followed by oral administration of 150 mL of water.
Blood sampling for platelet aggregation measurements
Platelet aggregation assessment was performed at three time-points: before administration of ticagrelor (baseline, sample 1) 20 ± 5 minutes (sample 2) and 60 ± 10 minutes (sample 3) after administration of ticagrelor. In all cases, the blood samples were drawn from a recently inserted venous catheter for repeated sampling or by direct venipuncture. The first 2-3 ml of blood was discarded to avoid platelet aggregation and then blood was collected in 
Outcome
We report residual platelet reactivity, percent IPR and proportion of patients with HRPR at baseline, 20 and 60 minutes.
Safety outcomes include TIMI major, minor or minimal bleeding within 24 hours after randomization.
Sample Size Calculation
In the ONSET/OFFSET study,(5) around 50% of patients had HRPR 30 minutes after LD ticagrelor (integral tablets). A recent study (15) has shown that administration of crushed ticagrelor tablets resulted in a mean plasma concentration of ticagrelor that was four to five times higher at 30 minutes compared with plasma concentration after administration of integral tablets. We assumed that chewed ticagrelor tablets would have at least as fast uptake as crushed ones. Given the antiplatelet effect of ticagrelor is linearly related to the blood concentration of ticagrelor,(2) we also assumed that 20% of patients with the novel ways of ticagrelor administration (crushed and chewed) would have HRPR 20 minutes after administration of LD. A sample of 100 patients (60 patients in the integral, 20 patients in the crushed and 20 patients in the chewed group) would give an 80% power to detect statistically significant differences in the HRPR rates.
Study population
Between November 2014 and July 2015, 102 patients were included in the study. Three patients were excluded due to technical reasons (e.g. inability to run the VerifyNow assay).
Ninety nine eligible patients were included in the final analysis. Percentage of HRPR in the three groups was compared using Chi-squared test. Pairwise comparisons were also performed using the same test. A p-value <0.05 was considered to indicate statistical significance. Due to the relatively small number of hypotheses being tested under the pairwise comparison, the likelihood of type I error was estimated as low and adjusted p values were not used. A forward stepwise binary logistic regression analysis was used to identify independent predictors of HRPR at 20 minutes after administration of ticagrelor. Known and potential predictors of HRPR were included in the model, in accordance with previous studies. (16, 17) Variables included in the model were age, gender, diabetes, Body Mass Index (BMI), smoking status, estimated glomerular filtration (eGFR) by the MDRD formula, platelet count, treatment with beta blockers or diuretics, PR at baseline and randomization group as a dichotomous variable (integral tablets versus crushed or chewed tablets). (16, 18) . Odds ratios (OR) with 95% confidence intervals (CI) are presented for the significant predictors.
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Results
Baseline characteristics are presented in Table 1 . There were no significant differences between the groups. 
Percent Inhibition of Platelet Reactivity:
We also calculated percent IPR values in order to correct for potential differences in baseline PRU. At 20 minutes, both crushed and chewed ticagrelor led to a significantly higher percent IPR compared to integral ticagrelor and chewed ticagrelor led to a higher percent IPR compared to crushed ticagrelor. Sixty minutes after the LD, all three groups achieved a substantial IPR (above 80%). However, the degree of IPR was significantly higher with chewed ticagrelor compared to the other formulations In a multivariate analysis including potential predictors of HRPR, integral ticagrelor administration (vs. crushed/chewed tablets combined) was the most powerful predictor of HRPR (OR for HRPR: 12.63; 95% CI: 4.22 -37.76). The other significant predictors of HRPR had a modest effect; PRU value at baseline (OR: 1.01; 95% CI: 1.00 -1.02) and BMI (OR:
1.15; 95% CI: 1.00 -1.32).
Figure 4
High Residual platelet reactivity (defined as > 208 platelet reactivity units) at baseline and 20 and 60 minutes after ticagrelor administration.*P-values for comparison of the three groups by Chi-squared test. Pairwise comparison between groups by chi-squared.
Safety outcome: One patient in the integral ticagrelor and one in the crushed ticagrelor group had a TIMI minor bleeding. One patient in the chewed ticagrelor group had a TIMI minimal bleeding.
Discussion
Our study shows that LD of crushed or chewed ticagrelor tablets achieved a more rapid and more effective platelet inhibition compared to LD of standard integral tablets. In addition, and to the best of our knowledge, for the first time, we show that administration of chewed ticagrelor tablets is feasible and may provide a faster and stronger platelet inhibition than administration of either crushed or integral tablets.
The chewed ticagrelor LD achieved impressive platelet inhibition properties. Within 20 minutes after LD, no patient had HRPR and a very low residual PR was observed (median PR 84 PRU). One hour after the LD, the median residual PR was 9 PRU, an exceptionally low value, not previously observed at any time point in a stable population treated with 180 mg LD ticagrelor followed by 90mg b.i.d. as a maintenance dose. (5) As the degree of platelet inhibition by ticagrelor is linearly related to the plasma concentration of the drug, (2) our data indicate that chewed ticagrelor achieved the most rapid and the highest rate of drug absorption. Furthermore, the faster and stronger platelet inhibition with chewed ticagrelor compared to crushed ticagrelor implies that other mechanisms than the mechanical "fractioning" of the tablets may have contributed to the improved absorption of the chewed ticagrelor. Initiation of enzymatic metabolic degradation of the tablet in the mouth due to the prolonged contact of the drug with the saliva as well as enhanced oral transmucosal absorption of the drug may be explanations for our results. These data may be of clinical importance in STEMI patients. According to an earlier trial, more than half of the STEMI patients treated with LD of integral ticagrelor still have HRPR up to 4 hours after administration of the drug. (7) Given the fact that suboptimal platelet inhibition is an important predictor of ischemic complications, such as stent thrombosis, (19) there is a time window after primary PCI, in which patients are at increased risk for ischemic complications.
In the ATLANTIC trial, despite a short median time between pre-hospital and in-hospital administration of ticagrelor, prehospital administration significantly reduced the risk of stent thrombosis, suggesting that fast and strong platelet inhibition at the time of PCI is clinically important. (20) . A significantly faster and stronger platelet inhibition, by overcoming the delayed intestinal absorption of orally administrated drugs, with chewed ticagrelor administration may improve clinical outcomes compared to integral tablets. A recent study in STEMI patients confirmed the superior pharmacodynamic properties of crushed ticagrelor compared to integral tablets. (17) Crushed tablet preparation in the prehospital setting, such as in the ambulance, may be cumbersome whereas chewed ticagrelor administration is more comfortable and according to our data, may provide a more effective platelet inhibition compared to crushed ticagrelor administration.
Theoretically, a stronger platelet inhibition at the time of PCI may increase the risk of bleeding. In the ATLANTIC trial, prehospital administration of ticagrelor appeared to be safe, compared to inhospital administration. In our study, the risk of bleeding was not increased with crushed or chewed ticagrelor administration.
With a small study population, other factors than the randomized treatment may be important. Therefore, we performed a multivariate analysis including potential confounders.
Integral ticagrelor administration was the most powerful predictor of HRPR (OR: 12.63; 95% CI: 4.22 -37.76). The only other independent predictors of HRPR had a modest effect; PRU value at baseline (OR: 1.01; 95% CI: 1.00 -1.02) and BMI (OR: 1.15; 95% CI: 1.00 -1.32).
Low responsiveness to clopidogrel in obese patients has previously been described. (21) Taking into account that ticagrelor LD is just the daily maintenance dose of the drug, while clopidogrel LD is 8-fold and prasugrel LD is 6-fold the daily dose, higher risk for HRPR in obese patients after ticagrelor administration might be due to a lower concentration of the drug. This finding should be taken into account when fast and strong platelet inhibition is desirable in an obese patient. However, at least in this setting, the tablet formulation appears much more important than BMI. With these data, we expand earlier knowledge on the importance of ticagrelor formulations for pharmacodynamic results.
Limitations
There are several limitations with our study. First, the most important limitation is the relatively small sample size, mainly in the crushed and chewed ticagrelor subgroups. We assumed that crushed and chewed ticagrelor would have similar pharmacodynamic properties and would be included as one group in the analysis. Despite the small numbers of patients, statistically significant differences in outcome between the subgroups could be identified. However, given the small sample size, only one method of platelet aggregation reported (VerifyNow), and the fact that comparison between chewed and crushed tablets derived from a post-hoc analysis, the difference between crushed and chewed tablets should be interpreted with caution and be regarded as hypothesis generating only. Second, we did not have pharmacokinetic data. Earlier studies have provided pharmacokinetic data for crushed ticagrelor indicating a linear relationship between plasma concentration of ticagrelor and effect on aggregation. Therefore we think it is reasonable to assume that faster and stronger inhibition of platelet activity with chewed tablets is caused by a faster and higher absorption after administration.
Conclusion
Novel ways of oral ticagrelor administration are feasible. Chewed ticagrelor tablets as a LD resulted in a faster and stronger platelet inhibition than integral tablets and in addition appeared to be faster than crushed tablets. This may have important clinical implications in STEMI patients and in cases when fast and potent platelet inhibition is desirable.
